NeuroMetrix Provides Update on Quell Health Cloud Including Promotion of Dr. Xuan Kong to Chief Data Scientist

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its data science initiative and the related Quell® Health Cloud.

Data science consists of the development of large cloud databases and the use of powerful analytical tools such as machine learning and artificial intelligence. The Quell device and its companion smartphone app connect seamlessly with the Quell Health Cloud. The cloud database stores the user’s demographic and clinical profile, health metrics including pain, sleep, activity and gait, and device utilization. The Quell Health Cloud has over thirty thousand registered Quell users, and growing. It is one of the largest chronic pain databases in the world. Initial research findings have already been presented at several scientific meetings and the Company expects to report additional results at clinical and connected health meetings over the next year.

In connection with the Company’s expanding data science initiative, Dr. Xuan Kong has been promoted to Chief Data Scientist. Dr. Kong has been with NeuroMetrix for nearly 20 years, most recently as SVP of Research and Intellectual Property. Dr. Kong has a broad background and experience base that encompasses data analytics, engineering, neurophysiology and business. He holds a PhD in Electrical Engineering from Johns Hopkins University and an MBA from Boston University.

“Chronic pain is a complex biopsychosocial condition that requires a customized treatment approach. Our vision is to leverage the unique data assets we are collecting in the Quell Health Cloud to deliver personalized pain relief for our customers,” said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. “I am looking forward to Xuan’s leadership in executing on this vision with his deep technical and product development expertise.”

spot_img

DON'T MISS

Related Articles